Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection

Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02140450

Enrollment

Registered

2014-05-16

Start date

2012-02-29

Completion date

2014-05-31

Last updated

2014-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular Pressure Change in Intravitreal Injection

Keywords

intraocular pressure, intravitreal injection, short term

Brief summary

To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular pressure rise after intravitreal injection.

Detailed description

Acute intraocular pressure elevation after intravitreal injection of bevacizumab was proven.Acute intraocular pressure elevation most probably is volume related and long term intraocular pressure elevation relates to pharmacologic features of the medications which results in anatomic changes in the angle of anterior chamber.Numerous studies found an intraocular pressure elevation right after the injection and quick normalization within maximally 30 minutes.This intraocular pressure elevation which lasts about 30 minutes, can result in irreversible visual loss especially in patients with critical remaining nerve fibers in the optic nerve head, as occurs in glaucomatous patients. Is there any way to prevent or even shorten this time of intraocular pressure elevation? We tried in our study to find a suitable response for a question above, so we used several anti-glaucoma agents (Timolol, Brimonidine, Acetazolamide, Mannitol versus placebo) as a prophylaxis to prevent acute intraocular pressure elevation right after intravitreal bevacizumab injection.

Interventions

DRUGTimolol

2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection

DRUGBrimonidine

Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection

DRUGAcetazolamide

Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection

DRUGMannitol

Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection

DRUGPlacebo

Artificial tears, 2 drops, 1-2 hours before intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* all patients who candidate for receiving intravitreal bevacizumab

Exclusion criteria

* patients who had advanced glaucoma * patients who received antiglaucoma agents in the past * patients who had corneal scar which affect IOP measurement

Design outcomes

Primary

Measure	Time frame	Description
change in IOP	0, 5, 10, 15, 30 minutes after injection	the change in intraocular pressure after intravitreal injection of bevacizumab

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026